

## Reverse Phase Protein Array (RPPA) Clinical Publications

Wulfkuhle JD, Yau C, Wolf DM, Vis DJ, Gallagher RI, Brown-Swigart L, Hirst G, Voest EE, DeMichele A, Hylton H, Symmans F, Yee DT, Esserman L, Berry D, Liu M, Park JW, Wessels L, van't Veer L, and Petricoin III, EF Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL JCO Precision Oncology 2018 :2, 1-20  
<http://ascopubs.org/doi/10.1200/PO.18.00024>

Olshen A, Wolf D, Jones EF, Newitt D, Veer LV', Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC. Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham). 2018 Jan;5(1):011014.  
<https://doi.org/10.1117/1.JMI.5.1.011014>

Einspahr JG, Curiel-Lewandrowski C, Calvert VS, Stratton SP, Alberts DS, Warneke J, Hu C, Saboda K, Wagener EL, Dickinson S, Dong Z, Bode AM, Petricoin III EF. Protein activation mapping of human sun-protected epidermis after an acute dose of erythemic solar simulated light. NPJ Precis Oncol. 2017; Epub Sep 21.  
<https://www.nature.com/articles/s41698-017-0037-7>

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN. Exploiting radiation-induced signaling to increase the susceptibility of resistant cancer cells to targeted drugs: AKT and mTOR inhibitors as an example. Mol Cancer Ther. 2017 Aug 11.  
<http://mct.aacrjournals.org/content/17/2/355>

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M. Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers. Br J Cancer. 2017 Aug 8;117(4):494-502.  
<https://www.nature.com/articles/bjc2017195>

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron SA, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle JD, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland Jones B, Liotta L, O'Shaughnessy JA, Carpten JD, Petricoin EF. Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. 2017 Apr 26. [Epub ahead of print]  
<http://clincancerres.aacrjournals.org/content/23/16/4919.long>

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M. Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine. *Oncotarget*. 2016 Dec 15. doi: 10.18632/oncotarget.14019. [Epub ahead of print]  
<https://doi.org/10.18632/oncotarget.14019>

Janda J, Burkett N, Blohm-Mangone K, Huang V, Curiel-Lewandrowski C, Alberts DS, Petricoin EF 3rd, Calvert VS, Einspahr J, Dong Z, Bode AM, Wondrak GT, Dickinson SE. Resatorvid-based Pharmacological Antagonism of Cutaneous TLR4 Blocks UV-induced NF- $\kappa$ B and AP-1 Signaling in Keratinocytes and Mouse Skin. *Photochem Photobiol*. 2016 Nov 10.  
<https://doi.org/10.1111/php.12659>

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M. A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray. *Mol Oncol*. 2016 Oct 14.  
<https://febs.onlinelibrary.wiley.com/doi/full/10.1016/j.molonc.2016.09.007>

Bowie M, Pilie P, Wulfkuhle J, Lem S, Hoffman A, Desai S, Petricoin E, Carter A, Ambrose A, Seewaldt V, Yu D, Ibarra Drendall C. Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer. *World J Clin Oncol*. 2015 Dec 10;6(6):299-311.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675916/>

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M. Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. *Oncotarget*. 2015 Sep 30.  
<https://doi.org/10.18632/oncotarget.5941>

Baldelli E, Haura EB, Crinò L, Cress WD, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M. Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine. *Proteomics Clin Appl*. 2015 Feb 11  
<https://doi.org/10.1002/prca.201400056>

Sereni MI, Baldelli E, Gambarà G, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M. Functional characterization of epithelial ovarian cancer histotypes by drug target-based protein signaling activation mapping: implications for personalized cancer therapy. *Proteomics*. 2015 Jan;15(2-3):365-73.  
<https://doi.org/10.1002/pmic.201400214>

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ. A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. *Breast Cancer Res Treat.* 2014 Oct;147(3):579-88.

<https://link.springer.com/article/10.1007%2Fs10549-014-3117-1>

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido EM, Edmiston K, Liotta L, Petricoin E. A Pilot Phase I/II Personalized Therapy Trial For Metastatic Colorectal Cancer: Evaluating the Feasibility of Protein Pathway Activation Mapping For Stratifying Patients To Therapy With Imatinib And Panitumumab. *J Proteome Res.* 2014 May 1

<https://pubs.acs.org/doi/10.1021/pr401267m>

Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P, Petricoin E 3rd, Liotta L, Milani G, Giordan M, Luppi M, Forghieri F, De Pol A, Cocco L, Basso G, Marmiroli S. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in Acute Myeloid Leukemia revealed by pathway selective inhibition and phosphoproteome analysis. *Leukemia.* 2014 Apr 4. doi: 10.1038/leu.2014.123.

<https://www.nature.com/articles/leu2014123>

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I. Stratification of clear cell renal cell carcinoma by signaling pathway analysis. *Expert Rev Proteomics.* 2014 Feb 27

<https://doi.org/10.1586/14789450.2014.893193>

Mueller C, Decarvalho AC, Mikkelsen T, Lehman NL, Calvert V, Espina V, Liotta LA, Petricoin EF 3rd. Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. *Cancer Res.* 2014 Feb 1;74(3):818-28

<http://cancerres.aacrjournals.org/content/74/3/818.long>

van der Veer A, van der Velden VH, Willemse ME, Hoogeveen PG, Petricoin EF, Beverloo HB, Escherich G, Horstmann MA, Pieters R, den Boer ML. Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia. *Blood Cancer J.* 2014 Feb 14;4:e181.

<https://www.nature.com/articles/bcj20145>

Robertson FM, Petricoin III EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV, Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhle J, Ye Z, Boley KM, Liu H, Moraes R, Zhang X, Demaria R, Barsky SH, Sun G, Cristofanilli M. Presence of anaplastic lymphoma kinase in inflammatory breast cancer. *Springerplus.* 2013 Oct 1;2:497.

<https://doi.org/10.1186/2193-1801-2-497>

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfschlegel JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models. *Breast Cancer Res.* 2013 Sep 18;15(5):R85.  
<https://doi.org/10.1186/bcr3480>

Wilson B, Liotta LA, Petricoin EF. Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation. *Mol Cell Proteomics.* 2013;12: 2522-2535.  
<https://doi.org/10.1074/mcp.M112.025346>

Hricik T, Federici G, Zeuner A, Alimena G, Tafuri A, Tirelli V, Varricchio L, Masiello F, Ciaffoni F, Vaglio S, Petricoin EF, Girelli G, Levine RL, Migliaccio AR. Transcriptomic and phospho-proteomic analyses of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. *Am J Hematol.* 2013 May 29  
<https://onlinelibrary.wiley.com/doi/full/10.1002/ajh.23487>

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C. Individualized therapy for metastatic colorectal cancer. *J Intern Med.* 2013 Mar 26  
<https://doi.org/10.1111/joim.12070>

Chiechi A, Novello C, Magagnoli G, Petricoin EF 3rd, Deng J, Benassi MS, Picci P, Vaisman II, Espina V, Liotta LA. Elevated TNFR1 and Serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. *Clin Cancer Res.* 2013 Mar 14  
<http://clincancerres.aacrjournals.org/content/19/9/2473.long>

Zupa A, Improta G, Silvestri A, Pin E, Deng J, Aieta M, Musto P, Nitti D, Mammano E, Liotta L, Belluco C, Wulfschlegel J, Petricoin E 3rd. A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping. *J Thorac Oncol.* 2012 Dec;7(12):1755-66.  
<https://doi.org/10.1097/JTO.0b013e3182725fc7>

Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M. Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations. *Clin Exp Metastasis.* 2012 Sep 29. [Epub ahead of print]  
<https://publicatt.unicatt.it/retrieve/handle/10807/111517/178227/Protein%20pathway%20activation%20mapping.pdf>

Wulfschlegel JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, Demichele A, Walch A, Bronger H, Becker I, Waldhor C, Hofler H, Esserman LJ, Liotta LA, Becker KF, Petricoin EF 3rd. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. *Clin Cancer Res.* 2012 Dec 1;18(23):6426-35.

<http://clincancerres.aacrjournals.org/content/18/23/6426.long>

Sirajuddin P, Das S, Ringer L, Rodriguez OC, Sivakumar A, Lee YC, Uren A, Fricke ST, Rood B, Ozcan A, Wang SS, Karam S, Yenugonda V, Salinas P, Petricoin E 3rd, Pishvaian M, Lisanti MP, Wang Y, Schlegel R, Moasser B, Albanese C. Quantifying the CDK inhibitor VMY-1-103's activity and tissue levels in an in vivo tumor model by LC-MS/MS and by MRI. *Cell Cycle*. 2012 Sep 14;11(20).

<https://doi.org/10.4161/cc.21988>

Hartsink-Segers SA, Zwaan CM, Exalto C, Luijendijk MW, Calvert VS, Petricoin EF, Evans WE, Reinhardt D, de Haas V, Hedtj rn M, Hansen BR, Koch T, Caron HN, Pieters R, Den Boer ML. Aurora kinases in childhood acute leukemia: the promise of Aurora B as therapeutic target. *Leukemia*. 2012 Sep 3. doi: 10.1038/leu.2012.256

<https://www.nature.com/articles/leu2012256>

Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A, Belluco C, Liotta L, Petricoin E, Pilati P, Nitti D. Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment. *Clin Colorectal Cancer*. 2012 Jun 1

<https://dx.doi.org/10.1016%2Fj.clcc.2012.05.003>

Zuurbier L, Petricoin EF, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines J, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Pieters R, Meijerink JP. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. *Haematologica*. 2012 Apr 4

<http://www.haematologica.org/content/97/9/1405.long>

Einspahr JG, Calvert V, Alberts DS, Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L, Longo C, Pellicani G, Prasad A, Sagerman P, Bermudez Y, Deng J, Bowden GT, Petricoin EF 3rd. Functional protein pathway activation mapping of the progression of normal skin to squamous cell carcinoma. *Cancer Prev Res*. 2012 Mar;5(3):403-13

<https://dx.doi.org/10.1158%2F1940-6207.CAPR-11-0427>

Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM. Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. *Br J Cancer*. 2011 Nov 1.

<https://www.nature.com/articles/bjc2011449>

Dey-Guha I, Wolfer A, Yeh AC, Albeck JG, Darp R, Leon E, Wulfkuhle J, Petricoin EF 3rd, Wittner BS, Ramaswamy S. Asymmetric cancer cell division regulated by AKT. *Proc Natl Acad Sci U S A*. 2011. Jul 14. [Epub ahead of print]

<https://doi.org/10.1073/pnas.1109632108>

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfschle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. *Mol Cancer Ther.* 2011 Jun 14.  
<http://mct.aacrjournals.org/content/10/8/1367.long>

Ibarra-Drendall C, Troch MM, Barry WT, Broadwater G, Petricoin EF 3rd, Wulfschle J, Liotta LA, Lem S, Baker JC Jr, Ford AC, Wilke LG, Zalles C, Kuderer NM, Hoffman AW, Shivraj M, Mehta P, Williams J, Tolbert N, Lee LW, Pilie PG, Yu D, Seewaldt VL. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. *Breast Cancer Res Treat.* 2011 Jun 7.  
<https://link.springer.com/article/10.1007%2Fs10549-011-1609-9>

Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin EF, Wulfschle J. Protein Pathway Activation Mapping of Brain Metastasis from Lung and Breast Cancers Reveals Organ Type Specific Drug Target Activation. *J Proteome Res.* 2011 Jul 1;10(7):3089-97.  
<https://doi.org/10.1021/pr200065t>

Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? *Cancer J.* 2011 Mar-Apr;17(2):89-95.  
<https://doi.org/10.1097/PPO.0b013e318212dd3d>

Frederick MJ, Vanmeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF 3rd, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. *Am J Pathol.* 2011 Feb;178(2):548-71.  
<https://dx.doi.org/10.1016%2Fj.ajpath.2010.10.044>

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfschle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL. Protein Microarray Analysis of Mammary Epithelial Cells from Obese and Non-Obese Women at High Risk for Breast Cancer: Feasibility Data. *Cancer Epidemiol Biomarkers Prev.* 2011 Jan 17.  
<http://cebp.aacrjournals.org/content/20/3/476.long>

Younossi ZM, Limongi D, Stepanova M, Pierobon M, Afendy A, Mehta R, Baranova A, Liotta L, Petricoin E. Protein Pathway Activation Associated with Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon (PEG-IFN) and Ribavirin (RBV). *J Proteome Res.* 2011 Jan 4. [Epub ahead of print]  
<https://pubs.acs.org/doi/abs/10.1021/pr100923u>

Maraldi T, Bertacchini J, Benincasa M, Guida M, De Pol A, Liotta LA, Petricoin E 3rd, Cocco L, Marmioli S. Reverse-phase protein microarrays (RPPA) as a diagnostic and therapeutic guide in multidrug resistant leukemia. *Int J Oncol*. 2011 Feb;38(2):427-35. <https://doi.org/10.3892/ijo.2010.850>

Matei D, Sill MW, Lankes HA, Degeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial. *J Clin Oncol*. 2011 Jan 1;29(1):69-75. <https://doi.org/10.1200/JCO.2009.26.7856>

Accordi B, Espina V, Giordan M, Vanmeter A, Milani G, Galla L, Ruzzene M, Sciro M, Trentin L, De Maria R, Te Kronnie G, Petricoin E, Liotta L, Basso G. Functional Protein Network Activation Mapping Reveals New Potential Molecular Drug Targets for Poor Prognosis Pediatric BCP-ALL. *PLoS One*. 2010 Oct 21;5(10) <https://doi.org/10.1371/journal.pone.0013552>

Zuurbier L, Homminga I, Calvert V, Winkel MT, Buijs-Gladdines JG, Kooi C, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Petricoin EF 3rd, Pieters R, Meijerink JP. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. *Leukemia*. 2010 Dec;24(12):2014-22. <https://doi.org/10.1038/leu.2010.204>

Espina V, Mariani BD, Gallagher RI, Tran K, Banks S, Wiedemann J, Huryk H, Mueller C, Adamo L, Deng J, Petricoin EF, Pastore L, Zaman S, Menezes G, Mize J, Johal J, Edmiston K, Liotta LA. Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. *PLoS One*. 2010 Apr 20;5(4):e10240. <https://doi.org/10.1371/journal.pone.0010240>

Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, Liotta LA, Petricoin EF, Pierobon M. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. *Lab Invest*. 2010 May;90(5):787-96. <https://doi.org/10.1038/labinvest.2010.47>

Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, Zaldivar F, Santos R, Tyson DR, Ornstein DK. Periprostatic Adipose Tissue as a Modulator of Prostate Cancer Aggressiveness. *J Urol*. 2009 Oct;182(4):1621-7. <https://doi.org/10.1016/j.juro.2009.06.015>

Pierobon M, Calvert V, Belluco C, Garaci E, Deng J, Lise M, Nitti D, Mammano E, Marchi FD, Liotta L, Petricoin E. Multiplexed Cell Signaling Analysis of Metastatic and Nonmetastatic Colorectal Cancer Reveals COX2-EGFR Signaling Activation as a Potential Prognostic Pathway Biomarker. *Clin Colorectal Cancer*. 2009 Apr;8(2):110-7.

<https://doi.org/10.3816/CCC.2009.n.018>

Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, Kay EW, Liotta LA, Petricoin EF. Quantitative cell signaling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. *J Pathol*. 2009 Mar 20.

<https://doi.org/10.1002/path.2561>

Grubb R, Deng J, Pinto P, Mohler J, Chinnaiyan A, Rubin M, Linehan W, Liotta L, Petricoin EF, Wulfkuhle J. Pathway Biomarker Profiling of Localized and Metastatic Human Prostate Cancer Reveal Metastatic and Prognostic Signatures. *J Proteome Res*. 2009 Mar 10. [Epub ahead of print]

<https://doi.org/10.1021/pr8009337>

Vanmeter AJ, Rodriguez AS, Bowman ED, Harris CC, Deng J, Calvert VS, Silvestri A, Fredolini C, Chandhoke V, Petricoin EF 3rd, Liotta LA, Espina V. LCM and protein microarray analysis of human NSCLC: Differential EGFR phosphorylation events associated with mutated EGFR compared to wild type. *Mol Cell Proteomics*. 2008 Oct;7(10):1902-24.

<https://doi.org/10.1074/mcp.M800204-MCP200>

Espina VA, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, Vanmeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. *Mol Cell Proteomics*. 2008 Oct;7(10):1998-2018.

<https://doi.org/10.1074/mcp.M700596-MCP200>

Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA and Petricoin EF. Multiplexed Cell Signaling Analysis of Human Breast Cancer: Applications for Personalized Therapy. *J of Prot Res*. 2008 Apr;7(4):1508-17.

<https://doi.org/10.1021/pr7008127>

Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA. Reverse phase protein microarrays for monitoring biological responses. *Methods Mol Biol*. 2007;383:321-36.

[https://doi.org/10.1007/978-1-59745-335-6\\_21](https://doi.org/10.1007/978-1-59745-335-6_21)

Zhou, J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin EF, Zhang Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. *PNAS* 2007. Oct 9;104(41):16158-63.

<https://doi.org/10.1073/pnas.0702596104>

Sheehan KM, Gulmann, C, Eichler GS, Weinstein, J, Barrett HL, Kay EW, Conroy RM, Liotta LA, Petricoin EF, Signal Pathway Profiling of Epithelial and Stromal Compartments of Colonic Carcinoma Reveal Epithelial-Mesenchymal Transition *Oncogene*, 2007 10;27(3):323-31.

<https://doi.org/10.1038/sj.onc.1210647>



Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X, Eichler GS, Johann DJ, Qualman S, Tsokos M, Krishnan K, Helman LJ, Liotta LA. Phosphoprotein Signal Pathway Mapping: Akt/mTOR Pathway Activation Association with Childhood Rhabdomyosarcoma Survival. *Cancer Research*. 2007;67(7):3431–4  
<https://doi.org/10.1158/0008-5472.CAN-06-1344>

Calvert VS, Collantes R, Elariny H, Afendy A, Baranova A, Mendoza M, Goodman Z, Liotta LA, Petricoin EF, and Younossi ZM. A Systems Biology Approach to the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD): Molecular Network Analysis of Human Adipose Tissue Can Distinguish Non-alcoholic Steatohepatitis (NASH) from Non-Progressive Simple Steatosis. *Hepatology*. 2007. 46(1) 166-172.  
<https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.21688>

Do TV, Symowicz JC, Berman DM, Liotta LA, Petricoin EF 3rd, Stack MS, Fishman DA. Lysophosphatidic Acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. *Mol Cancer Res*. 2007 Feb;5(2):121-31  
<https://doi.org/10.1158/1541-7786.MCR-06-0319>

Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, and Benz CC. Breast cancer growth prevention by statins. *Cancer Res*. 2006 Sep 1;66(17):8707-14.  
<https://doi.org/10.1158/0008-5472.CAN-05-4061>

Gulmann C, Sheehan K, Kay E, Liotta L, Petricoin E 3rd. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. *J Pathol*. 2006 Mar 3;208(5):595-606  
<https://doi.org/10.1002/path.1958>

Gulmann C, Espina V, Petricoin E, Longo, DL, Santi M, Knutsen T, Raffeld M, Jaffe ES, Liotta LA, Feldman AL. Proteomic analysis of apoptotic pathways reveal prognostic factors in follicular lymphoma. *Clinical Cancer Research* 2005 Aug 15;11(16):5847-55.  
<https://doi.org/10.1158/1078-0432.CCR-05-0637>

Belluco C, Mammano E, Petricoin E, Prevedello L, Calvert V, Liotta L, Nitti D, Lise M. Kinase substrate protein microarray analysis of human colon cancer and hepatic metastasis. *Clin Chim Acta*. 2005 May 24; [Epub ahead of print]  
<https://doi.org/10.1016/j.cccn.2005.03.024>

Petricoin EF 3rd, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. *J Clin Oncol*. 2005 May 20;23(15):3614-21.  
<https://doi.org/10.1200/JCO.2005.02.509>

Winters ME, Mehta AI, Petricoin EF 3rd, Kohn EC, Liotta LA. Supra-additive growth inhibition by a celecoxib analogue and carboxyamido-triazole is primarily mediated through apoptosis. *Cancer Res.* 2005 May 1;65(9):3853-60

<https://doi.org/10.1158/0008-5472.CAN-04-1989>

Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. *J Clin Invest.* 2005 May 2;115(5):1163-1176.

<https://doi.org/10.1172/JCI23424>

Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfschlegel JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. *Mol Cell Proteomics.* 2005 Apr;4(4):346-55. Epub 2005 Jan 25.

<https://doi.org/10.1074/mcp.T500003-MCP200>

Roberts E, Charboneau L, Espina V, Liotta L, Petricoin E, and Dreher K. Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure. *J Toxicol Environ Health A.* 2004 Jun 11;67(11):851-61.

<https://doi.org/10.1080/15287390490425768>

Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E, Liotta LA and Jaffe ES. Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. *J Lab Invest.* 2004 Feb;84(2):235-44.

<https://doi.org/10.1038/labinvest.3700051>

Espina V, Dettloff KA, Cowherd S, Petricoin 3rd EF, and Liotta LA. Use of proteomic analysis to monitor responses to biological therapies. *Expert Opin Biol Ther.* 2004 Jan;4(1):83-93.

<https://doi.org/10.1517/14712598.4.1.83>

Grubb RL, Calvert VS, Paweletz CP, Phillips JL, Linehan WM, Gillespie JW, Emmert-Buck MR, Liotta L, and Petricoin EF. Signal pathway profiling of prostate cancer using reverse phase protein arrays. *Proteomics*. 2003 Nov;3(11):2142-6.

<https://doi.org/10.1002/pmic.200300598>

Wulfkuhle JD., Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, and Petricoin EF. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase microarrays. *Proteomics*. 2003 Nov;3(11):2085-90.

<https://doi.org/10.1002/pmic.200300591>

Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KJ, Lee JK, Munson PJ, Petricoin EF, Liotta LA, and Weinstein JN. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. *Cancer Research*. 2003 Sep 1;63(17):5243-50.

<http://cancerres.aacrjournals.org/content/63/17/5243.long>

Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, Kohn EC, Emmert-Buck MR, Liotta LA, and Petricoin EF. Mitochondrial proteome: Altered cytochrome c oxidase subunit levels in prostate cancer. *Proteomics*. 2003 Sep;3(9):1801-10.

<https://doi.org/10.1002/pmic.200300461>

Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M, Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA, and Kohn EC. The granulin-epithelin precursor/PC-Cell-derived growth factor is a growth factor for epithelial ovarian cancer. *Clin Cancer Res*. 2003 Jan;9(1):44-51.

<http://clincancerres.aacrjournals.org/content/9/1/44.long>

Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y, and Steeg PS. Proteomics of human breast ductal carcinoma in situ. *Cancer Res*. 2002 Nov 15; 62(22):6740-9.

<http://cancerres.aacrjournals.org/content/62/22/6740.long>

Ahram M, Best C, Flaig M, Gillespie J, Leiva I, Chuaqui R, Zhou G, Shu H, Duray P, Linehan W, Raffeld M, Ornstein D, Zhao Y, Petricoin EF, and Emmert-Buck MR. Proteomic analysis of human prostate cancer. *Mol Carcinogenesis*. 2002 Jan;33(1):9-15.

<https://onlinelibrary.wiley.com/doi/abs/10.1002/mc.10019>

Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, and Petricoin EF 3rd. New approaches to proteomic analysis of breast cancer. *Proteomics*. 2001 Oct;1(10):1205-15.

[https://doi.org/10.1002/1615-9861\(200110\)1:10%3C1205::AID-PROT1205%3E3.0.CO;2-X](https://doi.org/10.1002/1615-9861(200110)1:10%3C1205::AID-PROT1205%3E3.0.CO;2-X)

Pawelcz CP, Charboneau L, Roth MJ, Bichsel VE, Simone NL, Chen T, Han N, Gillespie JW, Emmert-Buck M, Petricoin EF, and Liotta LA. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. *Oncogene*. 2001 Apr 12;20(16):1981-9. <https://doi.org/10.1038/sj.onc.1204265>

